Agendia

Agendia is a precision oncology company headquartered in Irvine, California. Founded with 143 employees, the company focuses on providing genomic information to guide breast cancer treatment decisions. Agendia generates approximately $50 million in annual revenue. Agendia offers two commercially available genomic profiling tests: MammaPrint® and BluePrint®. MammaPrint®, a 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test supported by prospective outcome data and included in national and international treatment guidelines. BluePrint®, an 80-gene molecular subtyping assay, evaluates the biology driving tumor growth. Together, these tests provide comprehensive genomic profiles to inform physician decisions throughout a patient's treatment journey. Beyond its existing assays, Agendia develops novel genomic tests and partners with companies to create digital treatment tools. This ongoing research focuses on building an extensive data resource to improve patient outcomes and meet the evolving needs of breast cancer patients and physicians. Agendia's assays are available through core biopsies or surgical specimens. To learn more about Agendia's assays and ongoing trials, please visit www.agendia.com.